In vitro activities of quinolones, β-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 6, 1996, Pages 1412-1418

  Fass, Robert J ^a,b   Barnishan, Jean ^a   Solomon, Marilyn C ^a   Ayers, Leona W ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b 4715 University Hospital Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFOPERAZONE; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; IMIPENEM; OFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TOBRAMYCIN; TROVAFLOXACIN;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ARTICLE; DRUG SCREENING; GRAM NEGATIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA;

EID: 0030005618     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.6.1412     Document Type: Article

References (22)

1. Applebaum, P. C., S. K. Spangler, and T. Tamarree. 1988. Susceptibility of 310 nonfermentative gram-negative bacteria to aztreonam, carumonam, ciprofloxacin, ofloxacin and fleroxacin. Chemotherapy (Basel) 34:40-45.
2. Bruckner, D. A., and P. Colonna. 1995. Nomenclature for aerobic and facultative bacteria. Clin. Infect. Dis. 21:263-272
3. Child, J., J. Andrews, F. Boswell, N. Brenwald, and R. Wise. 1995 The in vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. J. Antimicrob. Chemother. 35:869-876.
4. Fass, R. J. 1980. In vitro activity of cefoperazone against nonfermenters and Aeromonas hydrophila. Antimicrob. Agents Chemother. 18:483-486
5. Fass, R. J. 1983 Statistical comparison of the antibacterial activities of broad-spectrum penicillins against gram-negative bacilli Antimicrob. Agents Chemother. 24:156-162.
6. Fass, R. J. 1994 Use of frequency distribution curves, scattergrams and regression analyses to compare in vitro activities and describe cross-susceptibility and cross-resistance among four quinolones. J. Chemother. 6:368-376.
7. Fass, R. J., and J. Barnishan. 1980. In vitro susceptibilities of nonfermentative gram-negative bacilli other than Pseudomonas aeruginosa to 32 antimicrobial agents. Rev. Infect. Dis. 2:841-853.
8. Fass, R. J., J. Barnishan, and L. Ayers. 1995. Emergence of bacterial resistance to imipenem and ciprofloxacin in a university hospital. J. Antimicrob. Chemother. 36:343-353
9. Fass, R. J., W. W. Gregory, R. F. D'Amato, J. M. Matsen, D. N. Wright, and L. S. Young. 1990. In vitro activities of cefoperazone and sulbactam singly and in combination against cefoperazone-resistant members of the family Enterobacteriaceae and nonfermenters. Antimicrob. Agents Chemother. 34: 2256-2259.
10. Fass, R. J., and R. B. Prior. 1989. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate. Antimicrob Agents Chemother. 33:1268-1274.
11. Gooding, B. B., and R. N. Jones. 1993 In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone Antimicrob Agents Chemother. 37:349-353.
12. Gootz, T. D., K. E. Brighty, M. R. Anderson, B. J. Schmieder, S. L. Haskell, J. A. Sutcliffe, M. J. Castaldi, and P. R. McGuirk. 1994. In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial. Diagn. Microbiol. Infect. Dis. 19:235-243.
13. Kessler, R. E., J. Fung-Tomc, B. Kolek, B. Minassian, E. Huczko, E. Gradelski, and D. P. Bonner. 1995. In vitro activity of BMS-181139, a new carbapenem with potent antipseudomonal activity. Antimicrob. Agents Chemother 39:380-385.
14. Miller, L., and T. Berger. 1985. Bacteria identification by gas chromatography of whole cell fatty acids. Hewlett-Packard application note 228-41. Hewlett-Packard Co, Avondale, Pa.
15. National Committee for Clinical Laboratory Standards. 1993. Approved standard M7-A3. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically, 3rd ed. National Committee for Clinical Laboratory Standards, Villanova, Pa.
16. National Committee for Clinical Laboratory Standards. 1994. Fifth informational supplement M100-S5. Performance standards for antimicrobial susceptibility testing. National Committee for Clinical Laboratory Standards, Villanova, Pa.
17. Neu, H. C., and N.-X. Chin. 1994. In vitro activity of the new fluoroquinolone CP-99,219. Antimicrob. Agents Chemother. 38:2615-2622.
18. Nicoletti, G., and S. Stefani. 1994. Survey on antibiotic resistance in gram-negative non-fermentative bacteria other than pseudomonas in Italy. J Chemother. 6:20-24.
19. O'Donnell, E. D., E. H. Freimer, G. L. Gilardi, and R. Raeder. 1982. Comparative in vitro activities of N-formimidoyl thienamycin and moxalactam against nonfermentative aerobic gram-negative rods. Antimicrob. Agents Chemother. 21:673-675.
20. Strandberg, D. A., J. H. Jorgensen, and D. J. Drutz. 1983. Activities of aztreonam and new cephalosporins against infrequently isolated gram-negative bacilli. Antimicrob. Agents Chemother. 24:282-286.
21. Teng, R., S. C. Harris, D. E. Nix, J. J. Schentag, G. Foulds, and T. E. Liston. 1995. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J. Antimicrob. Chemother. 36:385-394.
22. Yabuuchi, E., T. Ito, E. Tanimura, N. Yamamoto, and A. Ohyama. 1981 In vitro antimicrobial activity of ceftizoxime against glucose-nonfermentative gram-negative rods. Antimicrob. Agents Chemother. 20:136-139.